Develops precision medicines for cancer treatment, utilizing a proprietary drug response predictor technology.
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on advancing oncology therapeutics through a unique approach utilizing drug-specific companion diagnostics developed by its proprietary drug response predictor technology. Headquartered in Cambridge, Massachusetts, the company is dedicated to developing treatments tailored to individual patient responses, aiming to optimize therapeutic outcomes in cancer care.
Allarity Therapeutics' robust pipeline includes several promising drug candidates in various stages of clinical development. Among these are Stenoparib, a poly-ADP-ribose polymerase inhibitor currently undergoing Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan-tyrosine kinase inhibitor targeted for the treatment of renal cell carcinoma; and IXEMPRA, a microtubule inhibitor being evaluated for metastatic breast cancer treatment.
Founded in 2004, Allarity Therapeutics leverages its innovative approach to drug development to bring potential breakthrough therapies to market. The company's commitment to precision medicine and personalized treatment strategies underscores its mission to address critical unmet needs in oncology, striving to improve outcomes and quality of life for cancer patients world wide.